In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 10, 1999, Pages 2571-2573

  Waites, Ken B ^a,b   Canupp, Kay C ^b   Kenny, George E ^c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA HOMINIS; PRIORITY JOURNAL;

EID: 0032869769     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.10.2571     Document Type: Article

References (15)

1. Bébéar, C. M., H. Renaudin, A. Boudjadja, and C. Bébéar. 1998. In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas. Antimicrob. Agents Chemother. 42:703-704.
2. Cohen, M. A., and M. D. Huband. 1997. In vitro susceptibilities of Mycoplasma pneumonias, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD131628, ciprofloxacin and comparator drugs. J. Antimicrob. Chemother. 40:308-309.
3. Cummings, M. C., and W. M. McCormack. 1990. Increase in resistance of Mycoplasma hominis to tetracyclines. Antimicrob. Agents Chemother. 34: 2297-2299.
4. Jones, R. N. 1994. Highlights from two international symposia on the subject of the expanded role of the Etest. Diagn. Microbiol. Infect. Dis. 19:149. (Foreword.)
5. Kenny, G. E., and F. D. Cartwright. 1991. Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273. Antimicrob. Agents Chemother. 35:1515-1516.
6. Kenny, G. E., and F. D. Cartwright. 1993. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob. Agents Chemother. 37:1726-1727.
7. Kenny, G. E., and F. D. Cartwright. 1996. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob. Agents Chemother. 40: 1048-1049.
8. Kenny, G. E., and F. D. Cartwright. 1997. Susceptibilities of human mycoplasmas to BAY 12-8039, abstr. F-143, p. 170. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Kenny, G. E., T. M. Hooton, M. C. Roberts, F. D. Cartwright, and J. Hoyt. 1989. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob. Agents Chemother. 33:103-107.
10. Meyer, R. D., and W. Clough. 1993. Extragenital Mycoplasma hominis infections in adults: emphasis on immunosuppression. Clin. Infect. Dis. 17(Suppl. 1):243-249.
11. Perea, E. J., J. Aznar, M. C. Garcia-Iglesias, and A. Pascual. 1996. Comparative in vitro activity of sparfloxacin against genital pathogens. J. Antimicrob. Chemother. 37(Suppl. A):19-25.
12. Renaudin, H., C. M. Bébéar, M. D. Aydin, A. Bryskier, and C. Bébéar. 1996. In vitro activity of levofloxacin against mycoplasmas, abstr. G-28, p. 286. In Abstracts of the 96th General Meeting of the American Society for Microbiology, 1996. American Society for Microbiology, Washington, D.C.
13. Waites, K. B., L. B. Duffy, T. Schmid, D. Crabb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob. Agents Chemother. 35:1181-1185.
14. Waites, K. B., D. M. Crabb, L. B. Duffy, and G. H. Cassell. 1997. Evaluation of the Etest for detection of tetracycline resistance in Mycoplasma hominis. Diagn. Microhiol. Infect. Dis. 27:117-122.
15. Waites, K. B., K. C. Canupp, and G. E. Kenny. 1999. In vitro susceptibilities of Mycoplasma hominis to moxifloxacin determined by Etest and agar dilution. Drugs 58(Suppl. 2):406-407.